Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
“Hair loss can be very debilitating. We should start thinking about more proactive strategies to mitigate risks.” — Yagiz Matthew Akiska, MD/MPH candidate, George Washington University
Dermatology February 24th 2026
British Medical Journal (The BMJ)
Real world observations estimate that 50% of people with obesity discontinue GLP-1 receptor agonists within 12 months of initiation.
Cardiology February 6th 2026
Healthline
“People are more used to taking pills than they are taking injections” but “90% of a person’s weight is the result of what they eat. There are no magic solutions.”
Ambulatory Care Nursing January 29th 2026
Conexiant
The FDA concluded that GLP-1 RA medications are not associated with suicidal ideation or behavior and is requesting corresponding updates to product labeling.
Endocrinology, Diabetes, Metabolism January 27th 2026
MedCentral
“These drugs are not weight loss drugs. “These are not diabetes drugs. These are drugs that have multiple purposes, including obesity and diabetes, and possibly they might even help protect the brain.” – Roger McIntyre, MD
Endocrinology, Diabetes, Metabolism January 21st 2026
Annals of Internal Medicine
GLP-1RAs may have little or no effect on risk for obesity-related cancers. Longer-term studies are needed to clarify potential risks or benefits.
Oncology, Medical January 20th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS